PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35455696-0 2022 The Influence of the CES1 Genotype on the Pharmacokinetics of Enalapril in Patients with Arterial Hypertension. Enalapril 62-71 carboxylesterase 1 Homo sapiens 21-25 35455696-1 2022 The angiotensin-converting enzyme inhibitor enalapril is hydrolysed to an active metabolite, enalaprilat, in the liver via carboxylesterase 1 (CES1). Enalapril 44-53 carboxylesterase 1 Homo sapiens 123-141 35455696-1 2022 The angiotensin-converting enzyme inhibitor enalapril is hydrolysed to an active metabolite, enalaprilat, in the liver via carboxylesterase 1 (CES1). Enalapril 44-53 carboxylesterase 1 Homo sapiens 143-147 35455696-2 2022 Previous studies show that variant rs71647871 in the CES1 gene affects the pharmacokinetics of enalapril on liver samples as well as healthy volunteers. Enalapril 95-104 carboxylesterase 1 Homo sapiens 53-57 35455696-8 2022 Pharmacogenetic markers of the CES1 gene may be a promising predictor for individualisation when prescribing enalapril. Enalapril 109-118 carboxylesterase 1 Homo sapiens 31-35 26076923-2 2016 In vitro incubation study of human liver, intestine and kidney s9 fractions demonstrated that the ACEI prodrugs enalapril, ramipril, perindopril, moexipril and fosinopril are selectively activated by CES1 in the liver. Enalapril 112-121 carboxylesterase 1 Homo sapiens 200-204 33963573-0 2021 Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. Enalapril 36-45 carboxylesterase 1 Homo sapiens 10-14 33963573-1 2021 BACKGROUND AND OBJECTIVE: Enalapril is a prodrug and needs to be activated by carboxylesterase 1 (CES1). Enalapril 26-35 carboxylesterase 1 Homo sapiens 78-96 33963573-1 2021 BACKGROUND AND OBJECTIVE: Enalapril is a prodrug and needs to be activated by carboxylesterase 1 (CES1). Enalapril 26-35 carboxylesterase 1 Homo sapiens 98-102 33963573-2 2021 A previous in vitro study demonstrated the CES1 genetic variant, G143E (rs71647871), significantly impaired enalapril activation. Enalapril 108-117 carboxylesterase 1 Homo sapiens 43-47 33963573-4 2021 A prospective, multi-dose, pharmacokinetics, and pharmacodynamics (PK/PD) study was conducted to determine the impact of the CES1 G143E variant on enalapril steady-state PK and PD in healthy volunteers. Enalapril 147-156 carboxylesterase 1 Homo sapiens 125-129 33963573-14 2021 CONCLUSIONS: The CES1 loss-of-function G143E variant significantly impaired enalapril activation and its systolic blood pressure-lowering effect in healthy volunteers. Enalapril 76-85 carboxylesterase 1 Homo sapiens 17-21 28639420-0 2017 The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. Enalapril 24-33 carboxylesterase 1 Homo sapiens 49-53 28639420-1 2017 This study investigated the influence of variations in the carboxylesterase 1 gene (CES1) on the pharmacokinetics of enalapril. Enalapril 117-126 carboxylesterase 1 Homo sapiens 59-77 28639420-1 2017 This study investigated the influence of variations in the carboxylesterase 1 gene (CES1) on the pharmacokinetics of enalapril. Enalapril 117-126 carboxylesterase 1 Homo sapiens 84-88 26076923-6 2016 The CES1 activity on enalapril activation in human livers with the 143G/E genotype was approximately one-third of that carrying the 143G/G. Enalapril 21-30 carboxylesterase 1 Homo sapiens 4-8 24141856-3 2014 However, no studies have described the role of human CES1 in the activation of two commonly prescribed angiotensin-converting enzyme inhibitors: enalapril and ramipril. Enalapril 145-154 carboxylesterase 1 Homo sapiens 53-57 25832562-3 2015 Enalapril, a carboxyl ester prodrug, is reported to be metabolized by human carboxylesterase-1 (CES1) but not by carboxylesterase-2 (CES2) to its active metabolite enalaprilat. Enalapril 0-9 carboxylesterase 1 Homo sapiens 76-94 25832562-3 2015 Enalapril, a carboxyl ester prodrug, is reported to be metabolized by human carboxylesterase-1 (CES1) but not by carboxylesterase-2 (CES2) to its active metabolite enalaprilat. Enalapril 0-9 carboxylesterase 1 Homo sapiens 96-100 25919042-0 2015 Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Enalapril 112-121 carboxylesterase 1 Homo sapiens 10-28 25919042-1 2015 AIM: The aim of the present study was to investigate the effects of the carboxylesterase 1 (CES1) c.428G > A (p.G143E, rs71647871) single nucleotide variation (SNV) on the pharmacokinetics of quinapril and enalapril in a prospective genotype panel study in healthy volunteers. Enalapril 209-218 carboxylesterase 1 Homo sapiens 72-90 25919042-1 2015 AIM: The aim of the present study was to investigate the effects of the carboxylesterase 1 (CES1) c.428G > A (p.G143E, rs71647871) single nucleotide variation (SNV) on the pharmacokinetics of quinapril and enalapril in a prospective genotype panel study in healthy volunteers. Enalapril 209-218 carboxylesterase 1 Homo sapiens 92-96 25919042-7 2015 CONCLUSIONS: The CES1 c.428G > A SNV decreased enalaprilat concentrations, probably by reducing the hydrolysis of enalapril, but had no observable effect on the pharmacokinetics of quinapril. Enalapril 50-59 carboxylesterase 1 Homo sapiens 17-21 24141856-4 2014 Here, we studied recombinant human CES1- and CES2-mediated hydrolytic activation of the prodrug esters enalapril and ramipril, compared with the activation of the known substrate trandolapril. Enalapril 103-112 carboxylesterase 1 Homo sapiens 35-39 24141856-5 2014 Enalapril, ramipril, and trandolapril were readily hydrolyzed by CES1, but not by CES2. Enalapril 0-9 carboxylesterase 1 Homo sapiens 65-69